Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MCD 386

Next Previous
Search
Drug Profile

MCD 386

Alternative Names: CDD-0102; CDD-0102-J; MCD-386; MCD-386 Forte; MCD-386 Forte/Transderm; MCD-386 Transderm; MCD-386CR

Latest Information Update: 04 Nov 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Toledo
  • Developer Mithridion
  • Class Antidementias; Oxadiazoles; Pyrimidines; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Muscarinic M1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Progressive supranuclear palsy; Schizophrenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (PO, Controlled release)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Transdermal, Patch)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Progressive-supranuclear-palsy in USA (PO, Controlled release)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top